Exact Sciences (NASDAQ:EXAS) Releases Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Exact Sciences (NASDAQ:EXAS) issued its quarterly earnings results on Wednesday. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23, Zacks reports. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. Exact Sciences updated its FY 2025 guidance to EPS.

Exact Sciences Trading Up 1.7 %

Shares of NASDAQ:EXAS traded up $0.85 during midday trading on Wednesday, reaching $50.48. 3,321,382 shares of the company’s stock were exchanged, compared to its average volume of 2,211,632. The stock has a market cap of $9.34 billion, a price-to-earnings ratio of -43.14 and a beta of 1.24. Exact Sciences has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The firm’s 50 day simple moving average is $55.66 and its two-hundred day simple moving average is $60.17. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93.

Analysts Set New Price Targets

EXAS has been the topic of several research reports. The Goldman Sachs Group decreased their target price on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Bank of America decreased their price objective on Exact Sciences from $75.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Sanford C. Bernstein upped their target price on shares of Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Benchmark reissued a “buy” rating and issued a $65.00 price target on shares of Exact Sciences in a research note on Monday, January 13th. Finally, Jefferies Financial Group boosted their price target on shares of Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.